Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Recipharm in New German Market Collaboration with FHS Unternehmensberatung

Published: Wednesday, October 16, 2013
Last Updated: Wednesday, October 16, 2013
Bookmark and Share
FHS Unternehmensberatung to sell and market Recipharm’s development services to customers.

FHS Unternehmensberatung and Recipharm Pharmaceutical Development AB based in Stockholm have announced that they have entered into a collaboration.

FHS Unternehmensberatung will sell and market Recipharm’s development services, including formulation development, analytical development, manufacture of clinical trial material and stability studies, to customers in Austria, Germany and Switzerland.

“I am very excited about this collaboration”, says Torkel Gren, Sales Director, Recipharm Pharmaceutical Development AB. “FHS Unternehmensberatung has through its owner Fritz H. Speck an excellent knowledge of the contract development business and a very valuable network in German speaking countries. I am convinced that this will help us to reach out to new customers”.

“I am deeply impressed by the capabilities, the excellent experience and the staff's extraordinary team spirit at Recipharm PD” says Fritz Speck, owner of FHS Unternehmensberatung.

Speck continued, “To me it seems quite clear, that especially clients in the German-speaking market could benefit a lot from the attractive opportunities and multilingual experience at Recipharm PD. I look forward to a successful and pleasant cooperation with the team.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Recipharm Secures Additional Bank Financing for Continued Growth
Company has entered a new five-year SEK 1 500 million term loan facility with three of the largest banks.
Tuesday, July 14, 2015
Recipharm Invests SEK 8 Million in Pharmanest
Investment to support the development of Pharmanest’s lead drug candidate SHACT.
Friday, July 10, 2015
Recipharm Reduces Risk and Improves Compliance with Infor
Company will also help Recipharm continue to improve compliance with the EU-GMP code of practice.
Thursday, July 09, 2015
Recipharm Appoints New Sales Director, Development Services
Amine Tahiri has joined the Development Services Sales team with effect from 1 July 2015.
Tuesday, June 30, 2015
Recipharm Acquires OnTarget Chemistry
Company extends its offering into preclinical development services.
Tuesday, June 16, 2015
Recipharm Appoints Chief Strategy Officer
Company has appointed Jean-François Hilaire to the new position of CSO.
Thursday, June 04, 2015
Recipharm Signs Partnership Agreement with Follicum
Agreement in preparation for a clinical trial of the drug candidate FOL-005.
Thursday, June 04, 2015
Recipharm Appoints New General Manager
Appointment of Giorgio Bruno as General Manager of Recipharm Italia S.p.A.
Thursday, April 30, 2015
Recipharm is Commencing Negotiations with LIDDS
Collaboration on large-scale manufacture of Liproca® Depot.
Friday, April 24, 2015
Recipharm Makes Strategic Investment in Synthonics
Recipharm has purchased $2.0 million of preferred stock in the company.
Wednesday, April 15, 2015
Recipharm and Adroit Science Form Collaboration
Company will support Recipharm’s pharmaceutical development with high quality solid state characterization services.
Thursday, March 26, 2015
Recipharm Completes Korean Serialization Project for Abbott
Validation batches planned to be shipped to Korea mid-March 2015.
Thursday, March 19, 2015
Recipharm Appoints New Position of Vice President Quality Management
Appointment of Thomas Beck with effect from 1st April 2015.
Wednesday, March 11, 2015
Recipharm Ready for Serialization and Delivers Complex Project for China
Already supplied fifty seven (57) serialized batches.
Thursday, January 29, 2015
Recipharm Acquires Flamel Technologies
Company will purchase Flamel’s development and manufacturing facility located in Pessac, France.
Thursday, November 27, 2014
Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Study Questions Presence in Blood of Heart-Healthy Molecules from Fish Oil Supplements
A new study from the Perelman School of Medicine at the University of Pennsylvania questions the relevance of fish oil-derived SPMs and their purported anti-inflammatory effects in humans.
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Key Player in Diabetic Kidney Disease Revealed
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!